Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 123

1.

Prognostic importance of radiologic extranodal extension in HPV-positive oropharyngeal carcinoma and its potential role in refining TNM-8 cN-classification.

Huang SH, O'Sullivan B, Su J, Bartlett E, Kim J, Waldron JN, Ringash J, de Almeida JR, Bratman S, Hansen A, Bayley A, Cho J, Giuliani M, Hope A, Hosni A, Spreafico A, Siu L, Chepeha D, Tong L, Xu W, Yu E.

Radiother Oncol. 2019 Nov 8;144:13-22. doi: 10.1016/j.radonc.2019.10.011. [Epub ahead of print]

PMID:
31710939
2.

Characterization and outcomes of patients enrolled to multiple phase I cancer trials.

Kuehne N, Chen L, McDonald K, Wang L, Spreafico A, Hansen A, Razak ARA, Bedard PL, Siu LL, Shepshelovich D.

Cancer Chemother Pharmacol. 2019 Nov 8. doi: 10.1007/s00280-019-03989-x. [Epub ahead of print]

PMID:
31705269
3.

Prevalence and Associated Factors of Sever's Disease in an Athletic Population.

Martinelli N, Spreafico A, Tramacere I, Marcolli D, Valli F, Curci D.

J Am Podiatr Med Assoc. 2019 Sep;109(5):351-356. doi: 10.7547/17-105.

PMID:
31599666
4.

An Integrative Approach to Inform Optimal Administration of OX40 Agonist Antibodies in Patients with Advanced Solid Tumors.

Wang R, Gao C, Raymond M, Dito G, Kabbabe D, Shao X, Hilt E, Sun Y, Pak I, Gutierrez M, Melero I, Spreafico A, Carvajal RD, Ong M, Olszanski AJ, Milburn C, Thudium K, Yang Z, Feng Y, Fracasso PM, Korman AJ, Aanur P, Huang SA, Quigley M.

Clin Cancer Res. 2019 Nov 15;25(22):6709-6720. doi: 10.1158/1078-0432.CCR-19-0526. Epub 2019 Oct 1.

PMID:
31573956
5.

Plaster cast treatment for distal forearm fractures in children: which index best predicts the loss of reduction?

Ravier D, Morelli I, Buscarino V, Mattiuz C, Sconfienza LM, Spreafico AA, Peretti GM, Curci D.

J Pediatr Orthop B. 2019 Sep 26. doi: 10.1097/BPB.0000000000000678. [Epub ahead of print]

PMID:
31567893
6.

Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.

Oliva M, Huang SH, Xu W, Su J, Hansen AR, Bratman SV, Ringash J, Jang R, Cho J, Bayley A, Hope AJ, Chen E, Giuliani M, Waldron J, Weinreb I, Perez-Ordonez B, Chepeha D, Kim J, O Sullivan B, Siu LL, Spreafico A.

Eur J Cancer. 2019 Sep;118:112-120. doi: 10.1016/j.ejca.2019.06.019. Epub 2019 Jul 19.

PMID:
31330486
7.

HPV Status Improves Classification of Head and Neck Gray Zone Cancers.

Ren J, Xu W, Su J, Ren X, Bender N, Habbous S, de Almeida JR, Goldstein DP, Cheng D, Chen Z, Mirshams M, Rahini M, Huang SH, Spreafico A, Hansen A, Kim J, Waldron J, Perez-Ordonez B, Zhao Y, Hung R, Waterboer T, Liu G.

J Dent Res. 2019 Jul;98(8):879-887. doi: 10.1177/0022034519853771.

PMID:
31282843
8.

Validation of distant metastases risk-groups in oral cavity squamous cell carcinoma patients treated with postoperative intensity-modulated radiotherapy.

Hosni A, Huang SH, Chiu K, Xu W, Su J, Lu L, Bayley A, Bratman SV, Cho J, Giuliani M, Kim J, O'Sullivan B, Ringash J, Waldron J, Spreafico A, de Almeida JR, Chepeha DB, Irish JC, Goldstein DP, Hope A.

Radiother Oncol. 2019 May;134:10-16. doi: 10.1016/j.radonc.2019.01.014. Epub 2019 Jan 31.

PMID:
31005202
9.

An interim report on the investigator-initiated phase 2 study of pembrolizumab immunological response evaluation (INSPIRE).

Clouthier DL, Lien SC, Yang SYC, Nguyen LT, Manem VSK, Gray D, Ryczko M, Razak ARA, Lewin J, Lheureux S, Colombo I, Bedard PL, Cescon D, Spreafico A, Butler MO, Hansen AR, Jang RW, Ghai S, Weinreb I, Sotov V, Gadalla R, Noamani B, Guo M, Elston S, Giesler A, Hakgor S, Jiang H, McGaha T, Brooks DG, Haibe-Kains B, Pugh TJ, Ohashi PS, Siu LL.

J Immunother Cancer. 2019 Mar 13;7(1):72. doi: 10.1186/s40425-019-0541-0.

10.

Referrals to a Phase I Clinic and Trial Enrollment in the Molecular Screening Era.

Tan T, Rheaume M, Wang L, Chow H, Spreafico A, Hansen AR, Razak ARA, Siu LL, Bedard PL.

Oncologist. 2019 Jul;24(7):e518-e525. doi: 10.1634/theoncologist.2018-0808. Epub 2019 Mar 4.

PMID:
30833487
11.

Hyperprogressive disease in early-phase immunotherapy trials: Clinical predictors and association with immune-related toxicities.

Kanjanapan Y, Day D, Wang L, Al-Sawaihey H, Abbas E, Namini A, Siu LL, Hansen A, Razak AA, Spreafico A, Leighl N, Joshua AM, Butler MO, Hogg D, Chappell MA, Soultani L, Chow K, Boujos S, Bedard PL.

Cancer. 2019 Apr 15;125(8):1341-1349. doi: 10.1002/cncr.31999. Epub 2019 Feb 15.

PMID:
30768786
12.

Metal ion trend in patients with metal-on-metal total hip arthroplasty: a 10-year prospective study.

Sangaletti R, Spreafico A, Barbieri F, Ferrari R, Castelli CC.

Hip Int. 2018 Nov;28(2_suppl):43-47. doi: 10.1177/1120700018812991.

PMID:
30755113
13.

Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2.

Nguyen LT, Saibil SD, Sotov V, Le MX, Khoja L, Ghazarian D, Bonilla L, Majeed H, Hogg D, Joshua AM, Crump M, Franke N, Spreafico A, Hansen A, Al-Habeeb A, Leong W, Easson A, Reedijk M, Goldstein DP, McCready D, Yasufuku K, Waddell T, Cypel M, Pierre A, Zhang B, Boross-Harmer S, Cipollone J, Nelles M, Scheid E, Fyrsta M, Lo CS, Nie J, Yam JY, Yen PH, Gray D, Motta V, Elford AR, DeLuca S, Wang L, Effendi S, Ellenchery R, Hirano N, Ohashi PS, Butler MO.

Cancer Immunol Immunother. 2019 May;68(5):773-785. doi: 10.1007/s00262-019-02307-x. Epub 2019 Feb 11.

PMID:
30747243
14.

Randomized, Open-Label, Crossover Studies Evaluating the Effect of Food and Liquid Formulation on the Pharmacokinetics of the Novel Focal Adhesion Kinase (FAK) Inhibitor BI 853520.

Verheijen RB, van der Biessen DAJ, Hotte SJ, Siu LL, Spreafico A, de Jonge MJA, Pronk LC, De Vos FYFL, Schnell D, Hirte HW, Steeghs N, Lolkema MP.

Target Oncol. 2019 Feb;14(1):67-74. doi: 10.1007/s11523-018-00618-0.

15.

Feasibility Assessment of Using the Complete Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) Item Library.

Shepshelovich D, McDonald K, Spreafico A, Razak ARA, Bedard PL, Siu LL, Minasian L, Hansen AR.

Oncologist. 2019 Apr;24(4):e146-e148. doi: 10.1634/theoncologist.2018-0332. Epub 2019 Feb 6.

PMID:
30728278
16.

Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.

Kanjanapan Y, Day D, Butler MO, Wang L, Joshua AM, Hogg D, Leighl NB, Razak ARA, Hansen AR, Boujos S, Chappell M, Chow K, Sherwin B, Stayner LA, Soultani L, Zambrana A, Siu LL, Bedard PL, Spreafico A.

Eur J Cancer. 2019 Jan;107:1-7. doi: 10.1016/j.ejca.2018.10.017. Epub 2018 Dec 7.

PMID:
30529898
17.

Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma.

Oliva M, Spreafico A, Taberna M, Alemany L, Coburn B, Mesia R, Siu LL.

Ann Oncol. 2019 Jan 1;30(1):57-67. doi: 10.1093/annonc/mdy507.

18.

Sensitive tumour detection and classification using plasma cell-free DNA methylomes.

Shen SY, Singhania R, Fehringer G, Chakravarthy A, Roehrl MHA, Chadwick D, Zuzarte PC, Borgida A, Wang TT, Li T, Kis O, Zhao Z, Spreafico A, Medina TDS, Wang Y, Roulois D, Ettayebi I, Chen Z, Chow S, Murphy T, Arruda A, O'Kane GM, Liu J, Mansour M, McPherson JD, O'Brien C, Leighl N, Bedard PL, Fleshner N, Liu G, Minden MD, Gallinger S, Goldenberg A, Pugh TJ, Hoffman MM, Bratman SV, Hung RJ, De Carvalho DD.

Nature. 2018 Nov;563(7732):579-583. doi: 10.1038/s41586-018-0703-0. Epub 2018 Nov 14.

19.

Predictors of Early Recurrence Prior to Planned Postoperative Radiation Therapy for Oral Cavity Squamous Cell Carcinoma and Outcomes Following Salvage Intensified Radiation Therapy.

Hosni A, Huang SH, Chiu K, Xu W, Su J, Bayley A, Bratman SV, Cho J, Giuliani M, Kim J, O'Sullivan B, Ringash J, Waldron J, Spreafico A, Yu E, de Almeida JR, Monteiro E, Chepeha DB, Irish JC, Goldstein DP, Hope A.

Int J Radiat Oncol Biol Phys. 2019 Feb 1;103(2):363-373. doi: 10.1016/j.ijrobp.2018.09.013. Epub 2018 Sep 21.

PMID:
30244160
20.

Dual compartmental targeting of cell cycle and angiogenic kinases in colorectal cancer models.

Capasso A, Pitts TM, Klauck PJ, Bagby SM, Westbrook L, Kaplan J, Soleimani M, Spreafico A, Tentler JJ, Diamond JR, Arcaroli JJ, Messersmith WA, Eckhardt SG, Leong S.

Anticancer Drugs. 2018 Oct;29(9):827-838. doi: 10.1097/CAD.0000000000000673.

21.

A multi-arm phase I dose escalating study of an oral NOTCH inhibitor BMS-986115 in patients with advanced solid tumours.

Aung KL, El-Khoueiry AB, Gelmon K, Tran B, Bajaj G, He B, Chen T, Zhu L, Poojary S, Basak S, Qi Z, Spreafico A, Fischer BS, Desai J.

Invest New Drugs. 2018 Dec;36(6):1026-1036. doi: 10.1007/s10637-018-0597-6. Epub 2018 Apr 10.

22.

Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer.

Klauck PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, Selby HM, Spreafico A, Tentler JJ, Tan AC, Kim J, Arcaroli JJ, Purkey A, Messersmith WA, Kuida K, Eckhardt SG, Pitts TM.

BMC Cancer. 2018 Feb 5;18(1):136. doi: 10.1186/s12885-018-4036-z.

23.

First-in-human trial of the PI3Kβ-selective inhibitor SAR260301 in patients with advanced solid tumors.

Bédard PL, Davies MA, Kopetz S, Juric D, Shapiro GI, Luke JJ, Spreafico A, Wu B, Castell C, Gomez C, Cartot-Cotton S, Mazuir F, Dubar M, Micallef S, Demers B, Flaherty KT.

Cancer. 2018 Jan 15;124(2):315-324. doi: 10.1002/cncr.31044. Epub 2017 Oct 4.

24.

Lymph node ratio relationship to regional failure and distant metastases in oral cavity cancer.

Hosni A, McMullen C, Huang SH, Xu W, Su J, Bayley A, Bratman SV, Cho J, Giuliani M, Kim J, Ringash J, Waldron J, Spreafico A, Weinreb I, de Almeida JR, Brown DH, Irish JC, O'Sullivan B, Goldstein DP, Hope A.

Radiother Oncol. 2017 Aug;124(2):225-231. doi: 10.1016/j.radonc.2017.06.018.

PMID:
28838425
25.

Outcome following radiotherapy for head and neck basal cell carcinoma with 'aggressive' features.

Rishi A, Hui Huang S, O'Sullivan B, Goldstein DP, Lu L, Ringash J, Waldron J, Wells W, Sun A, Hope A, Chung P, Giuliani M, Spreafico A, Tong L, Xu W, Bayley A.

Oral Oncol. 2017 Sep;72:157-164. doi: 10.1016/j.oraloncology.2017.07.018. Epub 2017 Jul 27.

PMID:
28797452
26.

Differentially activated Src kinase in chemo-naïve human primary osteosarcoma cells and effects of a Src kinase inhibitor.

Laschi M, Bernardini G, Geminiani M, Manetti F, Mori M, Spreafico A, Campanacci D, Capanna R, Schenone S, Botta M, Santucci A.

Biofactors. 2017 Nov;43(6):801-811. doi: 10.1002/biof.1382. Epub 2017 Aug 8.

PMID:
28786551
27.

The Cisplatin Total Dose and Concomitant Radiation in Locoregionally Advanced Head and Neck Cancer: Any Recent Evidence for Dose Efficacy?

Carlsson L, Bratman SV, Siu LL, Spreafico A.

Curr Treat Options Oncol. 2017 Jul;18(7):39. doi: 10.1007/s11864-017-0482-0. Review.

PMID:
28555374
28.

Phase I dose-escalation study of milciclib in combination with gemcitabine in patients with refractory solid tumors.

Aspeslagh S, Shailubhai K, Bahleda R, Gazzah A, Varga A, Hollebecque A, Massard C, Spreafico A, Reni M, Soria JC.

Cancer Chemother Pharmacol. 2017 Jun;79(6):1257-1265. doi: 10.1007/s00280-017-3303-z. Epub 2017 Apr 19.

PMID:
28424962
29.

A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF-Mutant Colorectal Cancer.

van Geel RMJM, Tabernero J, Elez E, Bendell JC, Spreafico A, Schuler M, Yoshino T, Delord JP, Yamada Y, Lolkema MP, Faris JE, Eskens FALM, Sharma S, Yaeger R, Lenz HJ, Wainberg ZA, Avsar E, Chatterjee A, Jaeger S, Tan E, Maharry K, Demuth T, Schellens JHM.

Cancer Discov. 2017 Jun;7(6):610-619. doi: 10.1158/2159-8290.CD-16-0795. Epub 2017 Mar 31.

30.

Histological and Ultrastructural Characterization of Alkaptonuric Tissues.

Millucci L, Bernardini G, Spreafico A, Orlandini M, Braconi D, Laschi M, Geminiani M, Lupetti P, Giorgetti G, Viti C, Frediani B, Marzocchi B, Santucci A.

Calcif Tissue Int. 2017 Jul;101(1):50-64. doi: 10.1007/s00223-017-0260-9. Epub 2017 Mar 7.

PMID:
28271171
31.

Early adulthood body mass index, cumulative smoking, and esophageal adenocarcinoma survival.

Spreafico A, Coate L, Zhai R, Xu W, Chen ZF, Chen Z, Patel D, Tse B, Brown MC, Heist RS, Dodbiba L, Teichman J, Kulke M, Su L, Eng L, Knox J, Wong R, Darling GE, Christiani DC, Liu G.

Cancer Epidemiol. 2017 Apr;47:28-34. doi: 10.1016/j.canep.2016.11.009. Epub 2017 Jan 12.

PMID:
28088657
32.

Genotype-matched treatment for patients with advanced type I epithelial ovarian cancer (EOC).

Spreafico A, Oza AM, Clarke BA, Mackay HJ, Shaw P, Butler M, Dhani NC, Lheureux S, Wilson MK, Welch S, Zhang T, Yu C, Stockley T, Siu LL, Kamel-Reid S, Bedard PL.

Gynecol Oncol. 2017 Feb;144(2):250-255. doi: 10.1016/j.ygyno.2016.12.002. Epub 2017 Jan 3.

PMID:
28062115
33.

Distant Metastases Following Postoperative Intensity-Modulated Radiotherapy for Oral Cavity Squamous Cell Carcinoma.

Hosni A, Huang SH, Xu W, Su J, Bayley A, Bratman SV, Cho J, Giuliani M, Kim J, Ringash J, Waldron J, Spreafico A, De Almeidad J, O'Sullivan B, Goldstein D, Hope A.

JAMA Otolaryngol Head Neck Surg. 2017 Apr 1;143(4):368-375. doi: 10.1001/jamaoto.2016.3668.

PMID:
28033442
34.

Targeting the protein ubiquitination machinery in melanoma by the NEDD8-activating enzyme inhibitor pevonedistat (MLN4924).

Wong KM, Micel LN, Selby HM, Tan AC, Pitts TM, Bagby SM, Spreafico A, Klauck PJ, Blakemore SJ, Smith PF, McDonald A, Berger A, Tentler JJ, Eckhardt SG.

Invest New Drugs. 2017 Feb;35(1):11-25. doi: 10.1007/s10637-016-0398-8. Epub 2016 Oct 25.

35.

Impact of cisplatin dose intensity on human papillomavirus-related and -unrelated locally advanced head and neck squamous cell carcinoma.

Spreafico A, Huang SH, Xu W, Granata R, Liu CS, Waldron JN, Chen E, Ringash J, Bayley A, Chan KK, Hope AJ, Cho J, Razak AA, Hansen A, Jang R, Perez-Ordonez B, Weinreb I, Bossi P, Orlandi E, Licitra LF, Song Y, O'Sullivan B, Siu LL, Kim J.

Eur J Cancer. 2016 Nov;67:174-182. doi: 10.1016/j.ejca.2016.08.013. Epub 2016 Sep 24.

PMID:
27669504
36.

Antitumor activity of the aurora a selective kinase inhibitor, alisertib, against preclinical models of colorectal cancer.

Pitts TM, Bradshaw-Pierce EL, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Tentler JJ, McPhillips K, Klauck PJ, Capasso A, Diamond JR, Davis SL, Tan AC, Arcaroli JJ, Purkey A, Messersmith WA, Ecsedy JA, Eckhardt SG.

Oncotarget. 2016 Aug 2;7(31):50290-50301. doi: 10.18632/oncotarget.10366.

37.

Phase I trial of dacomitinib, a pan-human epidermal growth factor receptor (HER) inhibitor, with concurrent radiotherapy and cisplatin in patients with locoregionally advanced squamous cell carcinoma of the head and neck (XDC-001).

Prawira A, Brana-Garcia I, Spreafico A, Hope A, Waldron J, Razak AR, Chen EX, Jang R, O'Sullivan B, Giuliani M, Bayley A, Cho J, Wang L, Perez-Ordonez B, Weinreb I, Siu LL, Hansen AR.

Invest New Drugs. 2016 Oct;34(5):575-83. doi: 10.1007/s10637-016-0367-2. Epub 2016 Jun 11.

PMID:
27289242
38.

Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts.

Lieu CH, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG.

Oncotarget. 2015 Oct 27;6(33):34561-72. doi: 10.18632/oncotarget.5949.

39.

Point of care ultrasound (POCUS) telemedicine project in rural Nicaragua and its impact on patient management.

Kolbe N, Killu K, Coba V, Neri L, Garcia KM, McCulloch M, Spreafico A, Dulchavsky S.

J Ultrasound. 2014 Sep 20;18(2):179-85. doi: 10.1007/s40477-014-0126-1. eCollection 2015 Jun.

40.

Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models.

Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, Klauck PJ, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, Tan AC, Eckhardt SG.

Front Pharmacol. 2015 Jun 16;6:120. doi: 10.3389/fphar.2015.00120. eCollection 2015.

41.

Establishment of Four New Human Primary Cell Cultures from Chemo-Naïve Italian Osteosarcoma Patients.

Laschi M, Bernardini G, Geminiani M, Ghezzi L, Amato L, Braconi D, Millucci L, Frediani B, Spreafico A, Franchi A, Campanacci D, Capanna R, Santucci A.

J Cell Physiol. 2015 Nov;230(11):2718-27. doi: 10.1002/jcp.24996.

PMID:
25809010
42.

Human platelet releasates combined with polyglycolic acid scaffold promote chondrocyte differentiation and phenotypic maintenance.

Bernardini G, Chellini F, Frediani B, Spreafico A, Santucci A.

J Biosci. 2015 Mar;40(1):61-9.

43.

A first-in-human phase I, dose-escalation, multicentre study of HSP990 administered orally in adult patients with advanced solid malignancies.

Spreafico A, Delord JP, De Mattos-Arruda L, Berge Y, Rodon J, Cottura E, Bedard PL, Akimov M, Lu H, Pain S, Kaag A, Siu LL, Cortes J.

Br J Cancer. 2015 Feb 17;112(4):650-9. doi: 10.1038/bjc.2014.653. Epub 2015 Jan 27.

44.

Genomic testing in cancer: patient knowledge, attitudes, and expectations.

Blanchette PS, Spreafico A, Miller FA, Chan K, Bytautas J, Kang S, Bedard PL, Eisen A, Potanina L, Holland J, Kamel-Reid S, McPherson JD, Razak AR, Siu LL.

Cancer. 2014 Oct 1;120(19):3066-73. doi: 10.1002/cncr.28807. Epub 2014 Jun 24.

45.

Amyloidosis, inflammation, and oxidative stress in the heart of an alkaptonuric patient.

Millucci L, Ghezzi L, Paccagnini E, Giorgetti G, Viti C, Braconi D, Laschi M, Geminiani M, Soldani P, Lupetti P, Orlandini M, Benvenuti C, Perfetto F, Spreafico A, Bernardini G, Santucci A.

Mediators Inflamm. 2014;2014:258471. doi: 10.1155/2014/258471. Epub 2014 Apr 28.

46.

A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients.

Spreafico A, Chi KN, Sridhar SS, Smith DC, Carducci MA, Kavsak P, Wong TS, Wang L, Ivy SP, Mukherjee SD, Kollmannsberger CK, Sukhai MA, Takebe N, Kamel-Reid S, Siu LL, Hotte SJ.

Invest New Drugs. 2014 Oct;32(5):1005-16. doi: 10.1007/s10637-014-0106-5. Epub 2014 May 3.

47.

Proteomics and phosphoproteomics provide insights into the mechanism of action of a novel pyrazolo[3,4-d]pyrimidine Src inhibitor in human osteosarcoma.

Bernardini G, Laschi M, Serchi T, Spreafico A, Botta M, Schenone S, Arena S, Geminiani M, Scaloni A, Collodel G, Orlandini M, Niccolai N, Santucci A.

Mol Biosyst. 2014 Jun;10(6):1305-12. doi: 10.1039/c3mb70328b. Epub 2014 Mar 11.

PMID:
24615350
48.

Demystifying the role of tumor HPV status in recurrent and/or metastatic squamous cell carcinoma of the head and neck.

Spreafico A, Amir E, Siu LL.

Ann Oncol. 2014 Apr;25(4):760-2. doi: 10.1093/annonc/mdu095. Epub 2014 Feb 25. No abstract available.

PMID:
24569917
49.

Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models.

Flanigan SA, Pitts TM, Newton TP, Kulikowski GN, Tan AC, McManus MC, Spreafico A, Kachaeva MI, Selby HM, Tentler JJ, Eckhardt SG, Leong S.

Clin Cancer Res. 2013 Nov 15;19(22):6219-29. doi: 10.1158/1078-0432.CCR-13-0145. Epub 2013 Sep 17.

50.

Current phase II clinical data for ridaforolimus in cancer.

Spreafico A, Mackay HJ.

Expert Opin Investig Drugs. 2013 Nov;22(11):1485-93. doi: 10.1517/13543784.2013.831404. Epub 2013 Aug 21. Review.

PMID:
23964772

Supplemental Content

Loading ...
Support Center